Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03725761
Recruitment Status : Recruiting
First Posted : October 31, 2018
Last Update Posted : January 27, 2020
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Immunomedics, Inc.
Information provided by (Responsible Party):
University of Wisconsin, Madison

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 1, 2020
Estimated Study Completion Date : June 1, 2021